Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro

Gelijkaardige items

• IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors
  door: Molenaar, Remco J., et al.
  Gepubliceerd in: (2018)
• Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
  door: Wang, Feng, et al.
  Gepubliceerd in: (2021)
• Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
  door: Merchant, Shelby L., et al.
  Gepubliceerd in: (2019)
• Decitabine and Venetoclax for IDH1/2-mutated Acute Myeloid Leukemia
  door: Venugopal, Sangeetha, et al.
  Gepubliceerd in: (2021)
• Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
  door: Gupta, Charu, et al.
  Gepubliceerd in: (2020)